May 2, 2018 / 11:11 AM / 25 days ago

BRIEF-Medicenna Amends Protocol Of Phase 2B Recurrent Glioblastoma Study Of MDNA55

May 2 (Reuters) - Medicenna Therapeutics Corp:

* MEDICENNA AMENDS PROTOCOL OF PHASE 2B RECURRENT GLIOBLASTOMA STUDY OF MDNA55 IN RESPONSE TO STRONG SAFETY DATA AND EARLY EFFICACY READ-OUTS

* MEDICENNA THERAPEUTICS - AMENDS PROTOCOL OF PHASE 2B RECURRENT GLIOBLASTOMA STUDY WILL EXTEND EXPECTED TIMING TO COMPLETE ENROLLMENT IN STUDY TO Q42018

* MEDICENNA THERAPEUTICS CORP - HALF PATIENTS IN ONGOING PHASE 2B STUDY OF MDNA55 IN RECURRENT GLIOBLASTOMA (RGBM) HAVE BEEN RECRUITED Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below